Lyell Immunopharma sets $80 million private placement of common stock

Lyell Immunopharma, Inc. disclosed in an 8-K filing that on November 3, 2026 it entered into a Securities Purchase Agreement with institutional accredited investors. Under the agreement, the company agreed to sell and issue to the investors an aggregate of 7,428,040 shares of common stock, par value $0.0001 per share, at a purchase price of $10.77 per share, in a private placement transaction.¹

The closing of the private placement is scheduled for on or about November 4, 2026, pending customary closing conditions, with expected gross proceeds of approximately $80.0 million before expenses.¹

The sale is being conducted as an unregistered offering. Lyell is relying on the exemption under Section 4(a)(2) of the Securities Act of 1933, and the investors made representations typical for private placements of this kind; the shares will carry restrictive legends.¹

As part of the deal, Lyell committed to a follow-up registration process. The company agreed to file a registration statement with the SEC within 30 days of closing to register the shares for resale, and to work toward making that registration effective promptly, with cash penalties triggered if it fails to meet those obligations.¹

The filing included standard forward-looking statement language, noting that statements about the timing, size, and completion of the placement are forward-looking and not guarantees of future performance, carrying inherent risks and uncertainties.¹ The 8-K was signed on November 4, 2026 by Mark Meltz, Lyell's General Counsel.